This post is also available in:
简体中文 (Chinese)
Danish drugmaker Novo Nordisk has announced research collaborations with two U.S. biotech companies to strengthen its competitiveness in the treatment of cardiometabolic diseases.
Novo’s shares rose 49% last year as demand surged for weight-loss drug Wegovy. The collaboration with Omega Therapeutics and Cellarity Inc could lead to new treatments for obesity and a liver disease called MASH. The two companies will jointly conduct preclinical trial drug development, and Novo will bear R&D expenses of up to US$532 million.
This is part of a framework agreement signed by Novo in 2022 with US investment company Flagship Pioneering. Novo said the collaboration will bring innovations that the companies cannot accomplish alone.
(Source: Reuters Image source: freepik)
